Skip to main content
60°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ascendis Pharma ADR
(NQ:
ASND
)
122.80
-3.97 (-3.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ascendis Pharma ADR
< Previous
1
2
3
4
5
6
Next >
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
Today 14:42 EDT
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts.
Via
Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
October 08, 2024
Via
Benzinga
Looking Into Ascendis Pharma's Recent Short Interest
September 26, 2024
Via
Benzinga
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
September 25, 2024
BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139...
Via
Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
September 24, 2024
Via
Benzinga
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
September 22, 2024
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
$100 Invested In This Stock 10 Years Ago Would Be Worth $5,900 Today
August 09, 2024
Via
Benzinga
$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
July 18, 2024
Via
Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
September 22, 2024
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%
Via
Benzinga
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
September 16, 2024
BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by late 2025 due to its dosing schedule and potential safety benefits.
Via
Benzinga
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
September 16, 2024
Via
Benzinga
Exposures
Fossil Fuels
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
September 16, 2024
Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia.
Via
Benzinga
Exposures
Product Safety
Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
July 03, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
June 26, 2024
Via
Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today
May 31, 2024
Via
Benzinga
(ASND) - Analyzing Ascendis Pharma's Short Interest
May 28, 2024
Via
Benzinga
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
September 16, 2024
The companies could soon face off in the growth treatment market for children with a genetic disorder.
Via
Investor's Business Daily
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday
September 16, 2024
Via
Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
September 04, 2024
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow...
Via
Benzinga
Why Ascendis Pharma Stock Tumbled by 11% Today
September 04, 2024
A bottom-line whiff and reduced guidance made the company an outlier for the wrong reasons on Hump Day.
Via
The Motley Fool
Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout
September 04, 2024
Shares are poised to undercut their 50-day and 200-day lines, and the lower boundary of a base.
Via
Investor's Business Daily
$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today
May 17, 2024
Via
Benzinga
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
September 04, 2024
Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company...
Via
Benzinga
Core & Main Reports Downbeat Results, Joins Rev Group, PagerDuty, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
September 04, 2024
Via
Benzinga
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
August 13, 2024
Via
Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
August 12, 2024
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient...
Via
Benzinga
Exposures
Product Safety
Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid Drug
August 12, 2024
The company faced a number of regulatory setbacks that pushed its initial expected approval date out from April.
Via
Investor's Business Daily
Exposures
Product Safety
Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday
July 05, 2024
U.S. stock futures rise, Macy's receives higher offer, LGI Homes sells 571 homes, Telefonaktiebolaget records impairment charge, GFL declares dividend.
Via
Benzinga
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
May 15, 2024
Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August 14, 2024. TransCon PTH aims to address low calcium levels due to...
Via
Benzinga
Exposures
Product Safety
Masters In Trading - Saturday, May 11
May 11, 2024
In this recap of the most recent trading session, I discuss earnings results and the market rally seen throughout the past week.
Via
Talk Markets
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.